Freshworks Inc vs Revvity Inc — how do they compare? Freshworks Inc trades at $13.84 (market cap $3.56B), while Revvity Inc trades at $154.98 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 4.8× Freshworks Inc's market cap, and Revvity Inc pays a 0.18% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and Revvity Inc for 12 Days on average.
| FRSH | RVTY | |
|---|---|---|
Market Cap | $3.56B | $16.98B |
Volume | 9,066,454 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $13.92 | $157.36 |
52-Week Low | $6.88 | $82.26 |
Typical Hold Time | 39 Days | 12 Days |
Enterprise Value | $2.93B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.86, up 1.91% today, reflecting positive momentum following its Q2 2026 earnings beat. The stock exhibits a bullish technical trend with strong moving average signals, though the RSI suggests it may be approaching overbought territory. Fundamentally, the company has achieved a significant turnaround, posting its first GAAP profitable quarter in 2026 with revenue growth of 16% year-over-year, driven by strength in its employee experience portfolio and cost discipline.
The outlook is positive, supported by a 50% analyst buy rating and a consensus price target of $14.60, implying modest upside. Key opportunities include continued AI monetization and market share gains, while risks involve heightened competition in the SaaS sector and the need to sustain recent profitability improvements amid economic uncertainty.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →